Evidence map›Paper›PMID 37995679›Full record

ArticleCell reports2023

Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14.

Zoey A Miller, Arielle Mueller, TaeBeom Kim, Jennifer F Jolivert, Ray Z Ma, Sahil Muthuswami, April Park, Derek B McMahon, Kevin T Nead, Ryan M Carey and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06747390 (A Phase I Randomized Controlled Trial of Intratumoral Lidocaine Injection Before Transoral Robotic Surgery), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06747390 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase I Randomized Controlled Trial of Intratumoral Lidocaine Injection Before Transoral Robotic Surgery (TORS) and Neck Dissection for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

TypeinterventionalSponsorRyan CareyRan2025 to 2028Enrolled30ConditionsOropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell CarcinomaArmsLidocaine 1% Injectable Solution
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Ligand binding modes of the bitter taste receptor T2R14 and T2R46.Nature structural & molecular biology · 2026
    Article
  6. Review
  7. Intracellular and dual-site inhibition of a bitter taste GPCR.Cellular and molecular life sciences : CMLS · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. A deadly taste: linking bitter taste receptors and apoptosis.Apoptosis : an international journal on programmed cell death · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Extragustatory bitter taste receptors in head and neck health and disease.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zoey A MillerDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Pharmacology Graduate Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Arielle MuellerDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
TaeBeom KimDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jennifer F JolivertDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Ray Z MaDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Sahil MuthuswamiDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
April ParkDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Derek B McMahonDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Kevin T NeadDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ryan M CareyDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: ryan.carey@pennmedicine.upenn.edu.
Robert J LeeDepartment of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: rjl@pennmedicine.upenn.edu.
University of Pennsylvania · USThe University of Texas MD Anderson Cancer Center · US

Funding

PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM008076 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A · 1985 to 2023
$10.8M
Immune function of bitter taste receptors in human macrophagesR01AI167971 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Nithin Adappa, Robert J. Lee · 2022 to 2026
$2.5M
Bitter and sweet taste receptor physiology in airway ciliated cellsR01DC016309 · NIDCD · UNIVERSITY OF PENNSYLVANIA · PI LEE, ROBERT J. · 2018 to 2022
$2.1M
Development and validation of novel optical methods for direct screening of taste receptor activationR21DC020041 · NIDCD · UNIVERSITY OF PENNSYLVANIA · PI LEE, ROBERT J. · 2023 to 2024
$447k
NIAID NIH HHS R01 AI167971NIDCD NIH HHS R01 DC016309NIDCD NIH HHS R21 DC020041NIGMS NIH HHS T32 GM008076
6 · The paper itself

Abstract

Head and neck squamous cell carcinomas (HNSCCs) have high mortality and significant treatment-related morbidity. It is vital to discover effective, minimally invasive therapies that improve survival and quality of life. Bitter taste receptors (T2Rs) are expressed in HNSCCs, and T2R activation can induce apoptosis. Lidocaine is a local anesthetic that also activates bitter taste receptor 14 (T2R14). Lidocaine has some anti-cancer effects, but the mechanisms are unclear. Here, we find that lidocaine causes intracellular Ca

Indexed as

Head and Neck NeoplasmsPapillomavirus InfectionsApoptosisHumansLidocaineQuality of LifeReceptors, G-Protein-CoupledSquamous Cell Carcinoma of Head and NeckTasteLidocaineReceptors, G-Protein-Coupledanestheticapoptosisbitter agonistcalciumchemosensory receptorCP: Cancercyclic-AMPG-protein-coupled receptorHPV+ubiquitin-proteasome system

Identifiers

PMID37995679
PMCPMC10842818
OpenAlexW4388915227

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.